AI-Powered IVF Excellence
To develop and deploy Garbha.ai, India's first AI-driven fertility care platform that transforms IVF outcomes by replacing manual, subjective embryo assessments with intelligent, standardized AI predictions - ultimately improving IVF success rates to 88%+ while reducing treatment costs by up to 50%.
Location: India (with planned expansion to ASEAN, UAE, and US markets)
B2LSPRY Private Limited
Live Product Demo
Click to play demonstration video
Experience our AI-powered embryo analysis in action
Manual, Subjective Assessments in IVF:
Current embryo assessments in IVF are manual, subjective, and inconsistent, limiting success rates. With rising global demand, there's an urgent need for accurate, standardized methods to improve outcomes, reduce patient stress, and lower costs.
Embryo Quality Assessment Solution:
AI-powered embryo quality assessment system that automates and standardizes evaluations, delivering consistent, accurate predictions to optimize IVF success rates, reduce variability and costs, and enhance patient satisfaction.
India: $1.45B (7.8% CAGR) | APAC: $9B | Global: $26B
IVD market: $395M USD projected to grow at CAGR of 4.6% from 2024 to 2030
The Indian IVF market is valued at USD 1.06 billion (2023) and is projected to grow at a 7.8% CAGR through 2030, driven by over 28 million infertile couples and low IVF success rates of 30-35% per treatment cycle. Globally, the IVF market is estimated at USD 25.3 billion and expanding rapidly as fertility technologies gain wider adoption.
Primary (B2B): IVF Clinics and Fertility Centers
Secondary (B2B2C): Patients through clinic partnerships
Tertiary (B2B): Pharma companies for drug efficacy studies
Technology Status: Market ready with continuous innovation
Commercial Launch: Expected Q2 2026 after CDSCO Manufacturing License
Aligned with: SDG 3 (Sustainable Development Goal - Good Health and Well-being), SDG 5 (Gender Equality), SDG 9 (Industry, Innovation and Infrastructure)
End-to-end AI assessment from gametes to embryo transfer - maximizing success at every stage
AI analyzes sperm motility, morphology, and concentration for optimal selection - improving fertilization rates by 40%.
Automated tracking of follicle growth and maturation timing - ensuring precise ovulation prediction and egg retrieval.
Real-time oocyte maturity and quality grading - selecting the best eggs for fertilization with 92% accuracy.
Multi-stage CNN analysis from Day 1 to Day 5 - standardizing embryo selection with 88% success prediction.
AI-powered endometrial receptivity analysis - identifying the optimal transfer window for maximum implantation success.
Personalized pharmacogenomics treatment - AI-guided hormone therapy recommendations to reduce trial-and-error.
Delivery Model: SaaS solution with EMR integration
Market: $1.45B India | $25.3B Global opportunity
Multi-stage CNN where each stage focuses on different aspects of embryo development (Day 1-5). First stage classifies basic morphological features, second stage analyzes blastocyst development, compaction, and time-lapse characteristics.
Shows how model predictions evolve over time using time-lapse imaging. Displays viability scores across stages in timeline format for transparent AI decisions.
Combines embryo image data with non-image data (maternal age, genetic testing, lab conditions). CNN processes images while MLP processes clinical data, combined in fusion layer for final classification.
Grad-CAM/LRP generates heatmaps highlighting embryo regions influencing decisions. Reveals key features like inner cell mass and blastomere symmetry driving viability predictions.
Model Building → Explainability → Clinical Insights
Status: Completed
Phygital Module: Completed
Dubai and Singapore: In Progress
250 clinic installation into their timelapse hardware: In Discussion
5000+ IVF clinics across India initially, followed by global customer base
✓ Agnostic to microscope and hardware
✓ First comer advantage – Only solution with CDSCO clearance
✓ Phygital module offering genetic testing at clinic
✓ Complete AI ecosystem (Embryo Grading, Sperm Assessment, Oocyte Quality, ERA, PGx, Follicular Study)
| Features | Garbha.ai | Vitrolife | Life Whisperer | Embryonics |
|---|---|---|---|---|
| Embryo Assessment | ✓ | ✓ | ✓ | ✓ |
| Sperm Analysis | ✓ | ✗ | ✗ | ✓ |
| Oocyte Quality | ✓ | ✗ | ✗ | ✗ |
| ERA Analysis | ✓ | ✗ | ✗ | ✗ |
| Hardware Agnostic | ✓ | ✗ | ✓ | ✗ |
| CDSCO Approved | ✓ | ✗ | ✗ | ✗ |
| Price (Annual) | ₹3.5L | ₹12L | ₹8L | ₹6L |
✓ Only CDSCO approved AI solution in India
✓ Complete phygital ecosystem
✓ Hardware agnostic platform
✓ Integrated genetic testing
✓ End-to-end fertility care platform
✓ 90% gross margin with SaaS model
Cloudnine, Oasis – standardization and performance
800+ centers – cost-effective AI guidance
Apollo, Yashoda – regulatory & brand differentiation
Research and ART Act collaboration
Validation in 5 clinics, CDSCO Test license
50-75 clinics, regional webinars, CDSCO Manufacturing License
500+ clinics nationwide, ISO/CE readiness
ASEAN & GCC exports
Sales Channels: Direct B2B sales Year 1-2, Channel partners & EMR integrators from 2026
Awareness: Joint case studies, AI training workshops (CME), Digital presence, DBT-BIRAC events
SaaS Subscription: ₹3.5L/year per clinic
Per-cycle fee: ₹1,500-2,000 per IVF cycle
Add-on Modules: ₹75,000 per clinic
Export licensing: USD 5,000 per license
Clinical: Renew Healthcare, GBR Fertility
Technology: GCP Cloud, Edge AI Inception
Academic: ISB Health-AI, IIM Lucknow
Vision: Build India's fertility-AI ecosystem
| Regulatory Body | Approval Type | Status | Timeline |
|---|---|---|---|
| CDSCO India | Test License | ✅ Completed | Q3 2025 |
| CDSCO India | Manufacturing License | 🔄 In Progress | Q1 2026 |
| ISO | ISO 13485:2016 Medical Device | ✅ Obtained | Q3 2025 |
| ISO | ISO 27001:2022 Information Security | 🔄 In Progress | Q3 2026 |
| CE Mark | European Conformity | 📋 Planned | Q1 2027 |
| FDA | 510(k) Clearance | 📋 Planned | Q2 2028 |
✨ First & Only AI-Powered IVF Solution with Regulatory Clearance in India
Experienced leaders with proven track record in healthcare, AI, and business
Alumni of ISB
IIT-H CEO, B2LSPRY
Professor, Operations Management
Deputy Dean - Faculty and Research,
Executive Director (MIMH) at ISB
Business Advisor CEO,
Apollo Hospitals Chennai
Strategic Clinical Advisor
Clinical lead and medical director
GBR fertility center
MBBS MD & ISB PGPMAX Alumni
Co-Founder, B2LSPRY
MBBS
Pediatrician & Neonatologist
at USD 10 Million Pre-Money Valuation
• 18-24 months operational runway
• Targeting Series A within 24 months
• Clear path to profitability
• Strong IP portfolio
AI-based stimulation protocols tailored to each patient via Garbha PGx
Early identification of implantation failure risks through biomarker diagnostics
Plug-and-play AI software with existing IVF equipment and cloud repository
Collaborate with clinics, pharma, med-tech to establish AI-IVF Innovation Hub
Making every couple's dream of parenthood a reality
🌐 www.Garbha.ai